癌症（英文版）2016，Vol.35Issue(5)：60-63,4.DOI:10.1186/s40880-016-0105-3
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study
YenHou Chang 1ChienHsing Lu 2MingShyen Yen 1WaiHou Lee 1Yi Chang 1WeiPin Chang 3and ChiMu Chuang1
作者信息
- 1. Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan, China
- 2. Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung 40705, Taiwan, China
- 3. Department of Healthcare Management, Yuanpei University, Hsinchu 30015, Taiwan, China
- 折叠
摘要
关键词
Epithelial ovarian/tubal/and peritoneal cancer/Intraperitoneal chemotherapy/Propensity score/Survival/Clinical trialsKey words
Epithelial ovarian/tubal/and peritoneal cancer/Intraperitoneal chemotherapy/Propensity score/Survival/Clinical trials引用本文复制引用
YenHou Chang,ChienHsing Lu,MingShyen Yen,WaiHou Lee,Yi Chang,WeiPin Chang,and ChiMu Chuang..Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study[J].癌症（英文版）,2016,35(5):60-63,4.
